On September 2, 2022 Assoc. Prof. Dr. Teera Woratanarat, Lecturer of the Faculty of Medicine Chulalongkorn University Post a message via Facebook that Yesterday worldwide, 496,391 more people died, 1,307 more deaths, bringing the total to 608,462,390, with 6,497,437 deaths.
The top five with the most infections were Japan, South Korea, Russia, the United States and Taiwan. Yesterday, the number of new infections included countries from Europe and Asia, seven of the top 10 and 16 of the world’s top 20.
The number of new infections every day in the world now. from Asia and Europe together accounted for 87.08 percent of the world’s population, while the number of deaths accounted for 71.38%.
…the epidemic situation of Thailand
According to the Worldometer data this morning, the number of deaths was yesterday. The 14th highest in the world and 6th in Asia, although the Thai Ministry of Health has adjusted the reporting system from 1 May until the number of reports is greatly reduced.
…updating knowledge of COVID-19
1..”BA.2.75 as immune-resistant as BA.5″
If you remember, Omicron BA.2.75 was first discovered in India and gradually spread to many countries around the world. has been closely watched It is predicted that it may replace BA.5, which dominates the current global pandemic. because there is still a tendency to increase continuously in many countries
The little good news comes from the latest research by a team from Sweden’s Karolinska Institutet published in the journal Infectious Medicine, The Lancet Infectious Diseases, yesterday.
In essence, it was demonstrated that BA.2.75 is not immune to BA.5 (being less resistant to BA.5 is good news) and that some of the antibodies used in BA. It is also currently effective in treatments such as bebtelovimab, tixagevimab, and cilgavimab.
However, the transmission efficiency of BA.2.75 appears to be greater than that of the original strain. that spread It would lead to infection in many people. even though they have never been infected before and re-infection therefore must not be careless regular defense
2. “The efficacy of vaccines during BA.5 is lower than previous strains.”
The latest data from the US CDC was presented at the Advisory Committee on Vaccines (ACIP) yesterday, September 1, 2022.
point out that The efficacy in preventing hospitalization of current vaccines was significantly reduced during the BA.4/BA.5 period compared to the pre-epidemic BA.2 period.
The above information reflects our awareness of the importance of daily defensive behaviors. and the need for booster vaccinations Policy-level agencies should also consider the introduction of outbreak-specific vaccines for disease control.
3.Update Long COVID in the UK
The Office for National Statistics released the latest situation report on Long COVID on September 1, 2022.
According to the survey until the end of July 2022, there are approximately 2 million people in the UK suffering from COVID-19, accounting for 3.1% of the population.
As many as 1.7 million people have had it for at least 12 weeks (3 months), 892,000 (regarding half) have had it for more than a year, and 429,000 (regarding one-fifth) have had it for more than a year. 2 years
Importantly, if considering the number of cases reported as Long COVID, 681,000 (34%) were infected during the Omicron epidemic.
The impact of long-term COVID-19 is estimated to be around 1.5 million, or 73%, reported to affect their daily lives, with 384,000 (regarding one-fifth of all long-COVID cases). ) reported a significant impact on daily life.
The data from ONS UK above shows us that Omicron is also contributing to a large number of Long COVID problems in countries with high vaccination rates. And clearly affect the lives of patients. In addition, Long COVID will increase the risk of various chronic diseases. It can be followed by, as research around the world has pointed out.
Protecting yourself from infection is the best. …Thai situation, we still have many outbreaks every day. Please live consciously Protect yourself regularly Wearing a mask correctly can greatly reduce the risk.
refer
1.Sheward DJ et al. Evasion of neutralising antibodies by omicron sublineage BA.2.75. The Lancet Infectious Diseases. 1 September 2022.
2.Link-Gelles R. Updates on COVID-19 Vaccine Effectiveness during Omicron. ACIP. 1 September 2022.
3.Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 September 2022. Office for National Statistics, UK.
4.Shaffer L et al. Lots of long COVID treatment leads, but few are proven. PNAS. 1 September 2022.
